Financing 2.1 billion yuan: Why is Eli Lilly betting on this nuclear medicine company?
Summary
This article reviews July financing activity across the biotech sector and highlights several notable raises. AdvanCell, a radiopharmaceutical company backed by Eli Lilly, raised $315 million to advance its alpha-emitting cancer therapies and clinical program. The piece also covers funding for Crystalys Therapeutics, Celea Therapeutics, Beeline Medicines, Claris Biotherapeutics, Flare Therapeutics, and Ratio Therapeutics, each working on different drug-development pipelines. It emphasizes how investors continue to favor nuclear medicine, AI drug discovery, and other frontier therapeutic platforms. The article also notes strategic backing from large pharmaceutical companies and the commercial momentum behind these startups.
Funding
Amount
$400.0M
Total raised
Date
July 14, 2025
Announcement date
Investors
Agent Capital, Menlo Ventures, Nextech Invest, Sapphire Ventures, LLC, Velocity Capital, Abingworth, Third Rock Ventures, Oak HC/FT, Eventide Asset Management, yosemite, PureTech Health, Canada Pension Plan Investment Board, Lightstone Ventures, Catalio Capital Management, Morningside Group, Pontifax, Invus, Novo AS, Thrive Capital, Casdin Capital, S.R. One Ltd, Baillie Gifford, Samsara BioCapital, AVENIR, General Catalyst, RA Capital Management, Wellington Management, Aisling Capital, SymBiosis, Longwood Founders Fund, Sanofi-Genzyme BioVentures, Ally Bridge Group
Lead investors
Company
chaidiscovery.com
Funded company
AskAI Classifications
Sectors
General
Functions
General
Linked Companies
Edenia
$1M to $5M